cjc-1295 and ipamorelin & Blend (10mg) CJC-1295 (NO DAC) + Ipamorelin

Conveniently located in the heart of Houston, we make it effortless to access top-tier peptide treatments close to home

Transfusion 55 , 205219

Eur Rev Med Pharmacol Sci

55 A separate, phase 2, dose-escalation study found that by reducing the starting dose and increasing dose-escalation time to 8 weeks, gastrointestinal side effects could be reduced and study dropout rates were similar to that of placebo

FDA Registration Number - FR-4000009319664 Let's keep in touch

A Phase I/II Trial of Plerixafor/G-CSF Combined with IV Bu/Flu Conditioning Regimen In AML/MDS Patients Undergoing Allogenic Stem Cell Transplantation